drugset / Trial / NCT00834210

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

NCT00834210

Phase 4 Completed 171 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris

Timeline

Start
2008-12
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapsone Small molecule 5 % Topical
Comparator Tazarotene Small molecule 0.1 % Topical

Indications